Oncology Corporate Profile
Aeterna Zentaris Inc. is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Zoptrex™ / zoptarelin doxorubicin||cytotoxic peptide conjugate||Endometrial cancer||III|
|Zoptrex™ / zoptarelin doxorubicin||cytotoxic peptide conjugate||Ovarian cancer||II|
|Zoptrex™ / zoptarelin doxorubicin||cytotoxic peptide conjugate||Prostate cancer||II|
|AEZS-138||Disorazol Z-D-Lys6-LHRH conjugate||Various cancer types||Preclinical|
View additional information on product candidates here »